CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 129 enrolled
Drug / intervention
Topicort® (desoximetasone) Topical Spray, 0.25%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02340169
NCT02340169Phase 4Completed
CompareCT.gov

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With Topicort® (Desoximetasone) Topical Spray, 0.25% in Pediatric Patients With Plaque Psoriasis.

Sun Pharmaceutical Industries, Inc.·interventional·Posted Jan 16, 2015·Updated Mar 28, 2023

In Brief

A Phase 4 clinical trial evaluating Topicort® (desoximetasone) Topical Spray, 0.25% for Plaque Psoriasis. Completed, enrolled 129 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate the potential of Topicort® (desoximetasone) Topical Spray, 0.25% to suppress hypothalmic pituitary adrenal axis function. The secondary objectives are to evaluate the efficacy parameters, pharmacokinetics and adverse event profile.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 16, 2015
Enrollment StartJan 23, 2015
Primary CompletionNov 22, 2019
Study CompletionNov 22, 2021
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 11.5 years ago

Interventions

Topicort® (desoximetasone) Topical Spray, 0.25%drug

Topicort® (desoximetasone) Topical Spray, 0.25% applied to affected areas twice a day for 28 days